Delcath Systems   Report issue

For profit Phase 2 Phase 3
Founded: New York NY United States (1987)
Status: No NME R&D (1987)

Organization Overview

First Clinical Trial
2004
NCT00096083
First Marketed Drug
2023
melphalan (alkeran)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Delcath Systems Inc. | DELCATH SYSTEMS INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bile Duct Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Cholangiocarcinoma (Phase 3)

Liver Neoplasms (Phase 2)

Melanoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 8